Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Thyroid Eye Disease, Graves' Orbitopathy
Interventions
Teprotumumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
U.S. locations
8
States / cities
Beverly Hills, California • Miami, Florida • Skokie, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Thyroid Neoplasms, Goiter, Nodular, Thyroid Nodule, Graves' Disease, Hyperparathyroidism
Interventions
Superficial Cervical Plexus Block, Local Wound Infiltration, 0.9% saline, Marcaine
Procedure · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced May 21, 2026, 6:18 PM EDT
Terminated Not applicable Interventional Results available
Conditions
Amiodarone-Induced Thyrotoxicosis
Interventions
RFA
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Graves' Disease
Interventions
IMVT-1402
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
89
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 75 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Graves Disease, Hashimoto Disease
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Graves Disease
Interventions
WP1302, WP1302 placebo, methimazole
Drug · Combination Product
Lead sponsor
Worg Biotherapeutics Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Hunt, Arizona • Canoga Park, California • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Graves Disease
Interventions
BHV-1300
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
South Gate, California • Miami, Florida • Columbus, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Graves' Dysthyroid Ophthalmopathy, Thyroid Related Orbitopathy
Interventions
Rituximab
Drug
Lead sponsor
Silkiss, Rona Z., M.D., FACS
Individual
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Oakland, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced May 21, 2026, 6:18 PM EDT
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced May 21, 2026, 6:18 PM EDT
Completed Phase 2Phase 3 Interventional Results available
Conditions
Thyroid-associated Ophthalmopathy
Interventions
Rituximab, Saline, Methylprednisolone
Drug
Lead sponsor
Rebecca Bahn
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Thyroid Eye Disease
Interventions
Veligrotug (VRDN-001), Placebo
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Graves' Disease
Interventions
RAI treatment, ATD Group
Radiation · Drug
Lead sponsor
University of Florida
Other
Eligibility
Up to 18 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Gainesville, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Thyroid Eye Disease
Interventions
Observational cohort study, Batoclimab
Other · Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Glendora, California • Aurora, Colorado • Livonia, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Graves' Disease
Interventions
IMVT-1402, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
64
States / cities
Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 6:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
Conditions
Stroke, Ischemic, Stroke Hemorrhagic, Stroke (CVA) or TIA, Stroke, Acute, Traumatic Brain Injury, SCI - Spinal Cord Injury, Ehlers-Danlos Syndromes (EDS), Lupus Erythematosus, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Amyotrophic Lateral Sclerosis, Graves Disease, Muscular Dystrophies
Interventions
Use of Rare Beauty makeup products
Other
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Thyroid Cancer
Interventions
Skin Biopsy
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Healthy Volunteers
Interventions
Teprotumumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced May 21, 2026, 6:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
Conditions
Colon Cancer, Lung Cancer, Atrial Fibrillation, Diabetes Type 2, Obesity, Breast Cancer, Graves Disease, Osteoarthritis, Celiac Disease, Myocardial Infarction, Prostate Cancer
Interventions
SNP analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Graves Disease, Hyperthyroidism
Interventions
Potassium Iodide
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Bioavailability, Bioequivalence
Interventions
TEPEZZA, EDP
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Thyroid Eye Disease, TED
Interventions
focus groups and individual interviews as well as filling out questionnaires
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Hyperthyroidism
Interventions
Not listed
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Thyroid Eye Disease, TED
Interventions
Satralizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Beverly Hills, California • La Jolla, California • Wichita, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 21, 2026, 6:18 PM EDT
Conditions
Graves' Ophthalmopathy (GO)
Interventions
RVT-1401 (Administered via subcutaneous injection), Placebo (Administered via subcutaneous injection)
Drug · Other
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
12
States / cities
Beverly Hills, California • Pasadena, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced May 21, 2026, 6:18 PM EDT